TAKHZYRO Now Available in Alberta

2020-12-04T15:46:17-06:00

We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug Benefit List. Alberta is the first province